04/07/2025
Access to Tirzepatide (Mounjaro®) for Weight Management – Update for Patients
From 23 June 2025, following approval by NICE, tirzepatide (also known by the brand name Mounjaro®) will begin to be made available through specially commissioned NHS weight management services in primary care settings.
This is a positive development, and we know many people may be interested in whether they are eligible to access this medication.
Important things to know:
➡ This medication is not prescribed directly by GPs.
➡ Local NHS services are being developed so that eligible patients can be referred for treatment.
➡ At this stage, access is being prioritised for those with the highest clinical need.
Eligibility includes having a BMI of 40 or more (adjusted for ethnicity*) plus at least four of the following conditions:
➡ Type 2 diabetes
➡ High blood pressure
➡ Heart disease
➡ Obstructive sleep apnoea
➡ Abnormal blood fats (dyslipidaemia)
We understand that managing your weight can be difficult, and we’re here to support you in all aspects of your health and wellbeing. If and when referral pathways become available in our local area, we will update our patients and review eligibility on a case-by-case basis.
In the meantime, you can find public FAQs and eligibility information on the Cheshire and Merseyside ICB website here: https://www.cheshireandmerseyside.nhs.uk/posts/mounjaro-tirzepatide-access-in-cheshire-and-merseyside/
Thank you for your understanding while these services are being set up.
Sunlight Group Practice Team
The new weight management medication ‘Tirzepatide’ (brand name Mounjaro®) is shortly being made available to NHS patients to support weight loss.